河岡ラボについて - Overview

代表論文

1. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses.H5N1 influenza A viruses. Science 298:1840-1842. doi:10.1126/science.1062882. 2001.
2. Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, Suzuki H, Nishimura H, Mitamura K, Sugaya N, Usui T, Murata T, Maeda Y, Watanabe S, Suresh M, Suzuki T, Suzuki Y, Feldmann H, Kawaoka Y. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431:703-707. doi:10.1038/nature02951. 2004.
3. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 364:759-765. doi:10.1016/S0140-6736(04)16934-1. 2004. 
4. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH,  Nguyen KY, Pham ND, Nguyen HH, Yamada S, Muramoto Y, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108. doi:10.1038/4371108a. 2005.
5. Noda T, Sagara H, Yen A, Takada A, Kida, Cheng RH, Kawaoka Y. Architecture of ribonucleoprotein complexes in influenza A viruses particles. Nature 439:490-492. doi:10.1038/nature04378. 2006.
6. Shinya K, Ebina M, Yamada S, Ono, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature 440:435-436. doi:10.1038/440435a. 2006.
7. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, Muramoto Y, Ito M, Kiso M, Horimoto T, Shinya K, Sawada T, Kiso K, Usui T, Murata T, Lin Y, Hay A, Haire LF, Stevens DJ, Russell RJ, Gamblin SJ,  Skehel JJ, Kawaoka Y. Hemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444:378-382. doi:10.1038/nature05264. 2006.
8. Kobasa D, Jones, SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Kim JH, Halfmann P, Hatta M, Feldmann F, Alimonti JB, Fernando L,  Li Y, Katze MG, Feldmann H, Kawaoka Y. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445:319-323. doi:10.1038/nature05495. 2007.
9. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297, 1435-1442. doi:10.1001/jama.297.13.1435. 2007.
10. Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, Newton MA, Ahlquist P, Kawaoka Y. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454:890-893. doi:10.1038/nature07151. 2008.
11. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025. doi:10.1038/nature08260. 2009.
12. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of H1N1 influenza virus. Nature 459:931-939. doi:10.1038/nature08157. 2009.
13. Imai M, Watanabe H, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486:420-428. doi:10.1038/nature10831. 2012.
14. Watanabe T, Kiso M, FukuyamaS , Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa  H, Tashiro M, Kawaoka Y. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:551-555. doi:10.1038/nature12392. 2013.
15. Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, Feldmann H,  Kawaoka Y. An Ebola whole virus vaccine is protective in nonhuman primates. Science 348:439-442. doi:10.1126/science.aaa4919. 2015.
16. Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, Kinoshita N, Hattori SI, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Transmission of SARS-CoV-2 in Domestic Cats. N Engl J Med 383:592-594. doi:10.1056/NEJMc2013400. 2020.
17. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. N Engl J Med 386:995-998 doi:10.1056/NEJMc2119407. 2022.
18. Halfmann P, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer S, Darling T, Joshi A, Loeber S, Singh G, Foster S, Ying B, Case J, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio J, Hernandez-Ortiz J, Henry A, Ciouderis K, Florek K, Patel M, Odle A, Wong LY, Bateman A, Wang Z, Edara VV, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche A, Sordillo E, Chang L, Bakel H, Simon V, PSP study group, Douek D, Sullivan N, Thackray L, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby R, Seder R, Suthar M, Garcia-Sastre A, Schotsaert M, Suzuki T, Boon A, Diamond M, Kawaoka Y. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603:687-692. doi:10.1038/s41586-022-04441-6. 2022.
19. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med 386(15):1475-1477. doi: 10.1056/NEJMc2201933. 2022.
20. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann P, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R, ISAO study team, Okuda M, Murakami J, Duong C, Godbole S, Douek D, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond M, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Nature 607:119-127. doi: 10.1038/s41586-022-04856-1. 2022.
21. Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med 387(5):468-470. doi: 10.1056/NEJMc2207519. 2022.
22. Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612(7940):540-545. doi: 10.1038/s41586-022-05482-7. 2022.
23. Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, Ito M, Uraki R, Halfmann P, Watanabe S, Takeda M, Hasegawa H, Imai M, Kawaoka Y. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N Engl J Med 387(13):1236-1238. doi:10.1056/NEJMc2209952. 2022.
24. Takashita E, Yamayoshi S, Halfmann P, Wilson N, Ries H, Richardson A, Bobholz M, Vuyk W, Maddox R, Baker DA, Friedrich TC, O'Connor DH, Uraki R, Ito M, Sakai-Tagawa Y, Adachi E, Saito M, Koga M, Tsutsumi T, Iwatsuki-Horimoto K, Kiso M, Yotsuyanagi H, Watanabe S, Hasegawa H, Imai M, Kawaoka Y. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6. N Engl J Med 387:2094-2097. doi:10.1056/NEJMc2211845. 2022.
25. Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann P, Kawaoka Y. Efficacy of Antiviral Agents against Omicron BQ.1.1 and XBB Subvariants. N Engl J Med 388:89-91. doi:10.1056/NEJMc2214302. 2023.